ReviewProceedings of the American Thoracic Society2007
Role of CD4+ T cells in sarcoidosis.
Review in Proceedings of the American Thoracic Society, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 2 syntheses or guidelines pooled it, 123 citations in OpenAlex.
- Sarcoidosis as an Autoimmune Disease.Frontiers in immunology · 2019Pooled it
- Meta-analysis of genetic programs between idiopathic pulmonary fibrosis and sarcoidosis.PloS one · 2013Pooled it
- Clinical characteristics of pulmonary sarcoidosis in China: a retrospective, multicenter study.Annals of medicine · 2025Article
- Review
- Successful Treatment of Delayed Onset Nodules After Dermal Fillers Injection with Abrocitinib: A Case Report.Clinical, cosmetic and investigational dermatology · 2025Article
- Renin-Angiotensin-Aldosterone System: A Potential Source of Biomarkers and Therapeutic Targets for Sarcoidosis.American journal of respiratory and critical care medicine · 2024Article
- Imbalance of B-Cell Subpopulations in the Microenvironment of Sarcoidosis or Lung Cancer.Cells · 2024Article
- A Breakthrough in the Treatment of Necrobiosis Lipoidica? Update on Treatment, Etiopathogenesis, Diagnosis, and Clinical Presentation.International journal of molecular sciences · 2024Review
- Functional link between sarcoidosis-associated gene variants and quantitative levels of bronchoalveolar lavage fluid cell types.Frontiers in medicine · 2023Article
- Neurosarcoidosis, Coccidioidomycosis, or Both!International medical case reports journal · 2023Article
- Differential diagnosis of pulmonary sarcoidosis: a review.Frontiers in medicine · 2023Review
- Pulmonary sarcoidosis with a cavitary lesion in the lung caused by a TNF-α inhibitor: A case report.Respirology case reports · 2022Article
- Detection of Anti-Vimentin Antibodies in Patients with Sarcoidosis.Diagnostics (Basel, Switzerland) · 2022Article
- Radiotracers to Address Unmet Clinical Needs in Cardiovascular Imaging, Part 2: Inflammation, Fibrosis, Thrombosis, Calcification, and Amyloidosis Imaging.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- CD103 Expression on Regulatory and Follicular T Cells in Lymph Nodes, Bronchoalveolar Lavage Fluid and Peripheral Blood of Sarcoidosis Patients.Life (Basel, Switzerland) · 2022Article
- PAD-2-mediated citrullination of nucleophosmin provides an effective target for tumor immunotherapy.Journal for immunotherapy of cancer · 2022Article
- T-Follicular Helper-like Cells in Sarcoidosis: Lending a Helping Hand.American journal of respiratory and critical care medicine · 2021Article
- Article
- Effects of infliximab on lung and circulating natural killer cells, CD56+ T cells and B cells in sarcoidosis.BMJ open respiratory research · 2021Article
- T cell receptor sequencing in autoimmunity.Journal of life sciences (Westlake Village, Calif.) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Activated pulmonary CD4(+) T lymphocytes of the Th-1 type are essential for the inflammatory process in sarcoidosis, and IFN-gamma production is crucial for the characteristic granuloma formation. Both the T cells and their inflammatory mediators may constitute possible targets for immunotherapy. A particular T-cell subset, the T-cell receptor (TCR) AV2S3(+) bronchoalveolar lavage (BAL) CD4(+) T cells, is found at dramatically increased levels in the BAL fluid of human leukocyte antigen (HLA)-DRB1*0301-positive and/or HLA-DRB3*0101-positive patients with sarcoidosis. The AV2S3(+) BAL CD4(+) T cells strongly associate with the sarcoid inflammation, and future studies on this particular T-cell subset to reveal their specificity may lead to the identification of sarcoidosis-specific antigen(s). T-cell subpopulations with regulatory functions (i.e., natural killer T cells and T regulatory cells) have recently been described as abnormal in sarcoidosis. Dysfunctional regulatory T cells may allow T effector cells to contribute to the formation of granulomas, and they may thus be relevant for the inflammatory process in this disease. These findings are exciting news and will be of help in designing new treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.